Interactome screening implicates BAG6 as a suppressor of UBQLN2 misfolding in ALS/FTD

Ubiquilin-2 (UBQLN2) is a ubiquitin (Ub)-binding shuttle protein that is mutated in X-linked forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS/FTD-linked mutations in UBQLN2 disrupt its conformation, increasing its tendency to form cytoplasmic aggregates that may disrupt cellular regulation through loss-of-function (LOF) and gain-of-function (GOF) effects. Here, we performed quantitative mass spectrometry (MS)-based interactome analysis of wild-type (UBQLN2<sup>WT</sup>) and ALS-mutant UBQLN2 (UBQLN2<sup>ALS</sup>) proteins using inducible pluripotent stem cells (iPSCs) and induced motor neurons (iMNs). Proteins showing enhanced association with UBQLN2<sup>ALS</sup> proteins included PEG10, a known degradation target of UBQLN2, and BAG6, a chaperone involved in the triage of mislocalized proteins (MLPs). BAG6 knockdown inhibited the solubility recovery of both UBQLN2<sup>WT</sup> and UBQLN2<sup>ALS</sup> proteins following heat stress (HS), suggesting it functions as a UBQLN2 holdase. In addition, knockdown of BAG6 or knockout of UBQLN2 led to PEG10 accumulation, implicating both in PEG10 turnover; however, neither BAG6 nor UBQLN2 was required for PEG10 degradation in response to HS. A highly aggregation-prone UBQLN2<sup>4XALS</sup> mutant harboring four different ALS-associated mutations showed increased PEG10 binding and modestly delayed PEG10 turnover while PEG10 degradation was not significantly different between UBQLN2<sup>WT</sup> and iPSCs expressing a UBQLN2<sup>P497H</sup> clinical mutant. The combined findings implicate BAG6 as a UBQLN2 holdase and identify a suite of proteins whose altered binding may contribute to pathologic changes in UBQLN2-associated ALS/FTD.

Authors

Institutions

Publication Details

Journal
Frontiers in Molecular Neuroscience
Published
2026-01-05
DOI
https://doi.org/10.3389/fnmol.2025.1720347
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Interactome screening implicates BAG6 as a suppressor of UBQLN2 misfolding in ALS/FTD

Mark Scalf, Lloyd M. Smith, Sang Hwa Kim, Claire E. Boos et al.
Frontiers in Molecular Neuroscience
Amyotrophic Lateral Sclerosis Research
article

Interactome screening implicates BAG6 as a suppressor of UBQLN2 misfolding in ALS/FTD

Mark Scalf, Lloyd M. Smith, Sang Hwa Kim, Claire E. Boos, Randal S. Tibbetts, Akasha K Wilkemeyer
article en

Abstract

Ubiquilin-2 (UBQLN2) is a ubiquitin (Ub)-binding shuttle protein that is mutated in X-linked forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS/FTD-linked mutations in UBQLN2 disrupt its conformation, increasing its tendency to form cytoplasmic aggregates that may disrupt cellular regulation through loss-of-function (LOF) and gain-of-function (GOF) effects. Here, we performed quantitative mass spectrometry (MS)-based interactome analysis of wild-type (UBQLN2<sup>WT</sup>) and ALS-mutant UBQLN2 (UBQLN2<sup>ALS</sup>) proteins using inducible pluripotent stem cells (iPSCs) and induced motor neurons (iMNs). Proteins showing enhanced association with UBQLN2<sup>ALS</sup> proteins included PEG10, a known degradation target of UBQLN2, and BAG6, a chaperone involved in the triage of mislocalized proteins (MLPs). BAG6 knockdown inhibited the solubility recovery of both UBQLN2<sup>WT</sup> and UBQLN2<sup>ALS</sup> proteins following heat stress (HS), suggesting it functions as a UBQLN2 holdase. In addition, knockdown of BAG6 or knockout of UBQLN2 led to PEG10 accumulation, implicating both in PEG10 turnover; however, neither BAG6 nor UBQLN2 was required for PEG10 degradation in response to HS. A highly aggregation-prone UBQLN2<sup>4XALS</sup> mutant harboring four different ALS-associated mutations showed increased PEG10 binding and modestly delayed PEG10 turnover while PEG10 degradation was not significantly different between UBQLN2<sup>WT</sup> and iPSCs expressing a UBQLN2<sup>P497H</sup> clinical mutant. The combined findings implicate BAG6 as a UBQLN2 holdase and identify a suite of proteins whose altered binding may contribute to pathologic changes in UBQLN2-associated ALS/FTD.

Frontiers in Molecular NeuroscienceVol. 18
University of Wisconsin–Madison (US)
Openalex Percentile: Top 97%
Amyotrophic Lateral Sclerosis Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Interactome screening implicates BAG6 as a suppressor of UBQLN2 misfolding in ALS/FTD — Mark Scalf, Lloyd M. Smith, et al. · Frontiers in Molecular Neuroscience (2026) | TGRS Research Map | TGRS